A new study by U.S. scientists provides compelling evidence that two genes are linchpins in defining the course of immune restoration in HIV-positive individuals undergoing virus-suppressing therapy.
Nature Medicine posted the study online March 30. The findings explain why some subjects’ immune systems fail to have a sustained immune comeback, despite suppression of HIV-1 replication by highly active antiretroviral therapy (HAART), while others’ immune systems roar back.
The two genes are CCR5, an HIV-1 co-receptor or portal of entry for the virus into CD4+ T cells, and CCL3L1, an HIV-suppressing molecule that binds to CCR5.
“The new results suggest that we may be able to personalize the treatment of HIV as we might be able to predict, based on the presence of these gene variations, whether someone will have a better or worse immunological response when taking HAART,” said lead author Sunil K. Ahuja, M.D., professor of medicine, microbiology, infectious diseases and biochemistry at The University of Texas Health Science Center at San Antonio and director of the Veterans Administration Center for AIDS and HIV Infection at the South Texas Veterans Health Care System in San Antonio. He holds the university’s President’s Council Chair for Excellence in Medical Research.
“We categorized the copy number of the CCL3L1 gene and variations in the CCR5 gene into three categories designated as high, moderate and low genetic risk groups," said Matthew Dolan, M.D., co-lead author and professor of medicine at the Uniformed Services University, Bethesda, Md. Dr. Dolan also helped oversee the cohort of subjects at Wilford Hall Medical Center, San Antonio, which contributed to this study.
“Those HIV-positive persons categorized into the low genetic risk group did the best on HAART. In contrast, those categorized into the high genetic risk group initially did fine during the first two years of therapy, but then their immune reconstitution failed and their CD4 cell counts began to decline,” Dr. Dolan said.
A 2005 study by Dr. Ahuja and colleagues suggested that individuals with fewer copies of the CCL3L1 gene than the average found in people from their same ethnic background have increased risk of acquiring HIV-1 infection and progressing faster to AIDS. Also, previous studies by these researchers defined the CCR5 variations that confer protection.
“As those in the high and moderate genetic risk groups might be especially vulnerable to both increased AIDS risk and a poorer immune response during HAART, it might be important to keep a closer eye on such patients and perhaps even consider starting them on therapy earlier,” said Brian Agan, M.D., a co-author also from Wilford Hall Medical Center.
“When patients fare poorly on HAART, clinicians usually think about genetic mutations in the virus as a possible reason, but this study points to the importance of also alerting caregivers to the importance of a person’s CCL3L1-CCR5 genetic makeup as another possible factor for faring poorly on therapy,” added Hemant Kulkarni, M.D., a co-author from the Veterans Administration Center for AIDS and HIV Infection.
Mike McCune, M.D., Ph.D., chief of the Division of Experimental Medicine at the University of California, San Francisco, hailed the study as one with potentially important practical applications. “By showing that the same genetic makeup increases susceptibility to immune depletion and impaired immune recovery, the authors provide novel tools that may allow us to predict both those who will progress faster after HIV infection as well as those who might benefit from earlier initiation of HAART,” he said.
The study suggests the need for new thinking in HIV-1 management. “The current debate about when to initiate antiretroviral therapy might need to be redirected toward first assessing who should be considered for therapy, on the basis of the host genetic endowment,” Dr. Ahuja said.
Capt. Gregory Martin, M.D., U.S.N., program director for the Infectious Diseases Clinical Research Program at the Uniformed Services University, said, “The finding that CCL3L1-CCR5 genetic makeup has its greatest impact on immune recovery when persons were started on therapy with CD4+ counts of less than 350 cells/mm3 highlights the importance of starting persons on therapy earlier rather than later.”
Joel Kupersmith, M.D., chief research and development officer for the Veterans Health Administration, said, “Dr. Ahuja’s groundbreaking research is in line with the VA’s mission of providing personalized medicine for veterans. We look forward to the translation of these findings into improved care for HIV-infected veterans and HIV patients worldwide.” The Veterans Health Administration is a part of the U.S. Department of Veterans Affairs and in part funded this work.
The CD4+ restoration was more closely associated with number of copies of CCL3L1 than with CCR5 status. “This suggests that drugs that mimic or amplify the activity of CCL3L1 could be effective for HIV treatment,” Dr. Dolan said.
The above story is based on materials provided by University of Texas Health Science Center at San Antonio. Note: Materials may be edited for content and length.
Cite This Page: